drugset / Trial / NCT07247227
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This single-arm, multi-center study is to evaluate Sugemalimab plus platinum-based chemotherapy as first-line therapy for patients with locally advanced and metastatic NSCLC in a real-world setting.
Timeline
- Start
- 2023-10-10
- Primary completion
- 2027-05
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sugemalimab | Monoclonal antibody | 1200 mg | — |